These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 34312257)

  • 21. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
    Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
    J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enhanced FcRn-dependent transepithelial delivery of IgG by Fc-engineering and polymerization.
    Foss S; Grevys A; Sand KMK; Bern M; Blundell P; Michaelsen TE; Pleass RJ; Sandlie I; Andersen JT
    J Control Release; 2016 Feb; 223():42-52. PubMed ID: 26718855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Monomeric IgG1 Fc molecules displaying unique Fc receptor interactions that are exploitable to treat inflammation-mediated diseases.
    Ying T; Feng Y; Wang Y; Chen W; Dimitrov DS
    MAbs; 2014; 6(5):1201-10. PubMed ID: 25517305
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.
    Ng CM; Loyet KM; Iyer S; Fielder PJ; Deng R
    Eur J Pharm Sci; 2014 Jan; 51():51-8. PubMed ID: 23999033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of protein aggregates on characterization of FcRn binding of Fc-fusion therapeutics.
    Bajardi-Taccioli A; Blum A; Xu C; Sosic Z; Bergelson S; Feschenko M
    Mol Immunol; 2015 Oct; 67(2 Pt B):616-24. PubMed ID: 26254986
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels.
    Vaccaro C; Zhou J; Ober RJ; Ward ES
    Nat Biotechnol; 2005 Oct; 23(10):1283-8. PubMed ID: 16186811
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of critical IgG binding epitopes on the neonatal Fc receptor.
    Vaughn DE; Milburn CM; Penny DM; Martin WL; Johnson JL; Bjorkman PJ
    J Mol Biol; 1997 Dec; 274(4):597-607. PubMed ID: 9417938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. pH-dependent binding engineering reveals an FcRn affinity threshold that governs IgG recycling.
    Borrok MJ; Wu Y; Beyaz N; Yu XQ; Oganesyan V; Dall'Acqua WF; Tsui P
    J Biol Chem; 2015 Feb; 290(7):4282-90. PubMed ID: 25538249
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Robust recombinant FcRn production in mammalian cells enabling oriented immobilization for IgG binding studies.
    Magistrelli G; Malinge P; Anceriz N; Desmurs M; Venet S; Calloud S; Daubeuf B; Kosco-Vilbois M; Fischer N
    J Immunol Methods; 2012 Jan; 375(1-2):20-9. PubMed ID: 21939661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
    Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
    MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of the pH dependence of the neonatal Fc receptor/immunoglobulin G interaction using antibody and receptor variants.
    Raghavan M; Bonagura VR; Morrison SL; Bjorkman PJ
    Biochemistry; 1995 Nov; 34(45):14649-57. PubMed ID: 7578107
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel approach to investigate the effect of methionine oxidation on pharmacokinetic properties of therapeutic antibodies.
    Stracke J; Emrich T; Rueger P; Schlothauer T; Kling L; Knaupp A; Hertenberger H; Wolfert A; Spick C; Lau W; Drabner G; Reiff U; Koll H; Papadimitriou A
    MAbs; 2014; 6(5):1229-42. PubMed ID: 25517308
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of the interactions of rabbit neonatal Fc receptor (FcRn) with rabbit and human IgG isotypes.
    Szikora B; Hiripi L; Bender B; Kacskovics I; Iliás A
    PLoS One; 2017; 12(9):e0185662. PubMed ID: 28957416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efflux of monoclonal antibodies from rat brain by neonatal Fc receptor, FcRn.
    Cooper PR; Ciambrone GJ; Kliwinski CM; Maze E; Johnson L; Li Q; Feng Y; Hornby PJ
    Brain Res; 2013 Oct; 1534():13-21. PubMed ID: 23978455
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration.
    Smith B; Kiessling A; Lledo-Garcia R; Dixon KL; Christodoulou L; Catley MC; Atherfold P; D'Hooghe LE; Finney H; Greenslade K; Hailu H; Kevorkian L; Lightwood D; Meier C; Munro R; Qureshi O; Sarkar K; Shaw SP; Tewari R; Turner A; Tyson K; West S; Shaw S; Brennan FR
    MAbs; 2018 Oct; 10(7):1111-1130. PubMed ID: 30130439
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
    Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
    J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
    Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
    Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,).
    West AP; Bjorkman PJ
    Biochemistry; 2000 Aug; 39(32):9698-708. PubMed ID: 10933786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein.
    Suzuki T; Hashii N; Tada M; Ishii-Watabe A
    MAbs; 2021; 13(1):1923366. PubMed ID: 34030575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus.
    Wang JW; Wu WH; Huang TC; Wong M; Kwak K; Ozato K; Hung CF; Roden RBS
    J Virol; 2018 Aug; 92(15):. PubMed ID: 29743371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.